×
About 223 results

ALLMedicine™ Mycobacterium Kansasii Center

Research & Reviews  84 results

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium k...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017304
Antimicrobial Agents and Chemotherapy; Srivastava S, Boorgula GD et. al.

Mar 23rd, 2022 - There is limited high-quality evidence to guide the optimal treatment of Mycobacterium kansasii pulmonary disease. We retrospectively collected clinical data from 33 patients with M. kansasii pulmonary disease to determine the time-to-sputum cultu...

Drug resistance profiles and related gene mutations in slow-growing non-tuberculous myc...
https://doi.org/10.1080/20477724.2022.2049029
Pathogens and Global Health; Akrami S, Dokht Khosravi A et. al.

Mar 10th, 2022 - There are limited studies on the antibiotic resistance patterns of slowly growing mycobacteria (SGM) species and their related gene mutations in Iran. This study aimed to elucidate the antibiotic susceptibility profiles and the mutations in some g...

Consensus management recommendations for less common non-tuberculous mycobacterial pulm...
https://doi.org/10.1016/S1473-3099(21)00586-7
The Lancet. Infectious Diseases; Lange C, Böttger EC et. al.

Jan 30th, 2022 - The 2020 clinical practice guideline for the treatment of non-tuberculous mycobacterial pulmonary disease (NTM-PD) by the American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, a...

An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957488
Journal of Global Antimicrobial Resistance; Srivastava S, Pasipanodya JG et. al.

Dec 22nd, 2021 - The aim of this study was to determine and compare the efficacy of drugs to treat Mycobacterium kansasii (Mkn) pulmonary disease by performing minimum inhibitory concentration (MIC) determination and time-kill studies. We determined the MICs to 13...

Hypercalcaemia in Mycobacterium kansasii pulmonary infection.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634358
BMJ Case Reports; Flowers RC, Ocampo J et. al.

Dec 2nd, 2021 - A gentleman in his 60s with end-stage kidney disease status post kidney transplantation on prednisone and tacrolimus presented with generalised weakness for 7 days, associated with altered mental status. Investigations revealed pancytopenia, acute...

see more →

Guidelines  2 results

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768745
Clinical Infectious Diseases : an Official Publication Of... Daley CL, Iaccarino JM et. al.

Aug 17th, 2020 - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (wit...

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375621
The European Respiratory Journal; Daley CL, Iaccarino JM et. al.

Jul 9th, 2020 - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (wit...

see more →

News  3 results

Mycobacterium haemophilum: A Challenging Treatment Dilemma in an Immunocompromised Patient
https://www.mdedge.com/dermatology/article/208389/infectious-diseases/mycobacterium-haemophilum-challenging-treatment/page/0/2?channel=44

Sep 19th, 2019 - In addition to this change in antibiotic coverage, the patient’s medical oncologist tapered the patient’s immunosuppression considerably. The patient subsequently completed 12 months of therapy with clarithromycin, moxifloxacin, and rifabutin star.

Mycobacteria subset plagues pulmonary patients
https://www.mdedge.com/chestphysician/article/138111/pulmonology/mycobacteria-subset-plagues-pulmonary-patients
Heidi Splete, MDedge News

May 15th, 2017 - Nontuberculous mycobacteria accounts for an increasing percentage of pulmonary disease, and nonsurgical treatment alone has not shown effectiveness, according to data from a meta-analysis of 24 studies and 1,224 patients. The study results were pu.

Cutaneous Infection With Mycobacterium kansasii in a Patient With Myelodysplastic Syndrome and Sweet Syndrome
https://www.mdedge.com/dermatology/article/101110/contact-dermatitis/cutaneous-infection-mycobacterium-kansasii-patient
Jessica Sprague, MD, MS, Matthew Leibowitz, MD et. al.

Jul 7th, 2015 - To the Editor: A 68-year-old man with a history of myelodysplastic syndrome and recurrent Sweet syndrome presented with left leg lesions of 3 months’ duration. The lesions originated as a solitary nodule on the left calf and subsequently developed.

see more →